Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  
Google
Web www.equitybulls.com
Research

| More

Krishna Institute of Medical Sciences - Management Meet Update - Stepping up - BUY

Posted On: 2022-06-06 18:33:25 (Time Zone: IST)


Mr. Param Desai - Senior Research Analyst at Prabhudas Lilladher Pvt. Ltd.

We hosted Dr. Bhaskar Rao (MD), Dr. Abhinay (CEO) and Mr. Vikas (CFO) of Krishna Institute of Medical Sciences (KIMS), for 2 day NDR at Mumbai. Management indicated that KIMS will continue to grow at double digit. In near term Sunshine acquisition will aid growth. Further KIMS intends to create cluster based investment approach in Karnataka and Maharashtra region. KIMS have lean cost structure and given it is partnering with local doctors outside AP & Telangana region, management remains confident of achieving faster break even and +25% OPM across these new clusters over next 4-5 years. KIMS will be generating Rs8-10bn of operating cash flow over FY22-24 which will utilized to set up new units across Maharashtra and Karnataka region.

EBITDA has grown at 40% CAGR over FY18-22. Our FY23E & FY24E EBITDA stands marginally cut by 1-3%. We expect 20% EBIDTA CAGR over FY22-24E, with one of best in class return ratios at 22%/31% RoE/RoCE. Recommend Buy with target price of Rs1600/share, valuing at 20x EV/EBIDTA on FY24E.

- Sunshine acquisition to drive growth: KIMS recently acquired 51.07% stake in Sunshine Hospitals (600 bed capacity) at a total EV of Rs. 7.3bn, at 9.7x FY21 EV/EBITDA. Sunshine's current occupancy stands at 45% with ~70% of revenue comes from Ortho + Cardiac specialty. The objective of KIMS is to scale up other specialties which would aid occupancy. Further there will be synergies in consumables procurement and HR cost. The acquisition was done in Oct 2021- For Nov- March 2021, Sunshine has reported Rs. 1.9bn of revenues and pre IND AS EBITDA of Rs. 350mn.

Overall we expect Sunshine revenues to grow to Rs. 5.2bn and EBIDTA of Rs. 1.2bn by FY24E.

- New expansion - Will adopt cluster based approach: Management in its cluster based approached, looking forward to replicate AP and Telangana model in Maharashtra and Karnataka region. KIMS plan to commercialize ~1500 beds over next 4-5 years across Maharashtra and Karnataka region. The expansion will be combination of inorganic + greenfield expansion. More important company will partner with local doctors/consultant in specific micro market which will help to generate better footfalls and achieve faster break-even. KIMS will have full control of decision making in such partnership.

Overall we have factor in Rs. 8bn of capex over FY22-24E of which Rs. 5-6bn will be spent towards new units.

- Outlook for existing units (9 hospitals in AP and Telangana): KIMS intends to increase the current operational beds utilization from 2246 in FY22 to its optimal capacity to 3064 beds considering normalcy and demand environment continues to remain healthy going forward.

Overall we expect 6 % revenue and 8-10% EBIDTA CAGR over FY22-24E from its existing units.

Shares of Krishna Institute of Medical Sciences Limited was last trading in BSE at Rs. 1249.95 as compared to the previous close of Rs. 1251.80. The total number of shares traded during the day was 1245 in over 485 trades.

The stock hit an intraday high of Rs. 1257.95 and intraday low of 1234.55. The net turnover during the day was Rs. 1553275.00.


Click here to send ur comments or to feedback@equitybulls.com

Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only. www.equitybulls.com, its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. www.equitybulls.com or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.





Other Headlines:

CRISIL Ratings: Agrochemicals sector to see 7-9% growth amid modest exports

SBI Capital Markets: RBI Monetary Policy Dec'24 - RBI faces arduous task of managing all dynamics: Liquidity, Currency, Growth and Inflation

SBICAPS Monthly Ecocapsule Dec'24 : FY25 - A TALE OF TWO HALVES OR ONE OF FULL DESPAIR? - Executive Summary

CRISIL Ratings: Revenue growth of organised luggage makers to halve to 8-10%

CRISIL Ratings - Cement demand to grow at a moderate pace of 7-8% this fiscal

CRISIL Ratings: For small finance banks, RoA to dip ~40 bps this fiscal

Securitisation volumes witness strong growth; likely to reach ~Rs. 60,000 crore in Q2 FY2025: ICRA

CRISIL Ratings: Operating losses of state discoms to stay high despite 15-20% dip

CRISIL Ratings: Tamil Nadu garment exporters to see 8-10% revenue growth

CRISIL MI&A: Inflated natural rubber prices to puncture tyre maker margins

Infrastructure bond issuances by public sector banks to drive banks' bond issuances to an all-time high in FY2025: ICRA

CRISIL Ratings: Apparel retailers to stitch 8-10% growth with festivals, fast fashion

CRISIL Ratings: For ARCs, rising power consumption to boost recoveries from stressed operational thermal plants

Views of ICAI on SA 600 vs ISA 600

CRISIL Ratings: Wagon makers set to roll in ~20% revenue growth this fiscal

CRISIL Ratings: Basmati industry to see revenue grow ~4% on a high base this fiscal

CRISIL: Pharmaceutical sector set for 8-10% revenue growth this fiscal

CRISIL Ratings: Flexible packaging players' credit profiles to stay subdued this fiscal

Industry credit expected to grow over 12 per cent: FICCI-IBA Bankers' Survey

CRISIL Ratings: Decadal-low duty to push gold jewellery retailers' revenues up by 22-25%

CRISIL Ratings: Education loan AUM of NBFCs to top Rs 60,000 crore this fiscal

Evolving asset quality risks to impact growth and profitability of microfinance: ICRA

Near-term Consolidation; Focus Remains on Style & Sector Rotation - Axis Securities

CRISIL Ratings: Paper packaging volume to grow, but profitability to plumb lows

CRISIL MI&A: Corporate revenue growth likely moderated to 5-7% in April-June, the slowest in 15 quarters

CRISIL Ratings: Revenue growth of auto dealers to enter the slow lane this fiscal

Declining liquidity coverage ratios to slow down credit growth for banks: ICRA

CRISIL Ratings: Road developers to see slower revenue growth of 5-7% next fiscal

CRISIL Ratings: Small finance banks to grow advances 25-27% this fiscal

Global monetary easing to pick up pace - Puneet Pal, Head-Fixed Income, PGIM India Mutual Fund

Kotak Institutional Equities: Strategy: 1QFY25: Converging trends

CRISIL Ratings: Cement makers line up ~Rs 1.25 lakh crore capex over fiscals 2025-27

CRISIL Ratings: Urea import dependency to fall to 10-15% from this fiscal

CRISIL Ratings: 20% ethanol blending goal means more sugarcane utilisation

Kotak Institutional Equities: Automobiles & Components: 1QFY25 review: Steady quarter; demand outlook weakening

CRISIL MI&A: Macroeconomics First Cut - Goods exports fall, services soften

Kotak Institutional Equities: Consumer: 1QFY25 review- Uptick in staples, continued weakness in discretionary

CRISIL Ratings: Despite cash disbursement restriction gold-loan NBFCs shine

SBICAPS Report - The Green Pill: Labelled Bond Issuances, ESG Indices, Global Sustainable Funds

We expect the 10 yr benchmark bond yield to keep drifting lower gradually - PGIM India Mutual Fund

Strategy: Faith, froth and fundamentals by Kotak Institutional Equities

Earnings growth should be the key driver of returns hereon - Vinay Paharia - CIO, PGIM India Mutual Fund

IT Services: ERD services: Auto pulse-challenges ahead - Kotak Institutional Equities

Banks, Diversified Financials : Strong on expected lines across BFSI - Quarterly Review - Kotak Institutional Equities

Metals & Mining: SC ruling-empowers the states; marginal negative impact - Kotak Institutional Equities

CRISIL Ratings: Revised deposit norms unlikely to be onerous for HFCs

CRISIL Ratings: 6 gigawatt renewable energy storage to be added by fiscal 2028

CRISIL Ratings: Thermal share in power generation to dip over 500 bps next fiscal

Indian bond market issuances exceeded $105 billion, $25 billion new equity issued in FY24 - Shri Pramod Rao, ED, SEBI

One third of Nifty 100 companies hire thousands of young talent on apna.co


Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2020